Angeloylgomisin O

31940319

Objective
To estimate healthcare expenditures that could be impacted by advanced diagnostic testing for patients hospitalized with meningitis or encephalitis

Methods
Patients hospitalized with meningitis (N = 23,933) or encephalitis (N = 7,858) in the U.S. were identified in the 2010-2014 Truven Health MarketScan Commercial Claims and Encounters Database using ICD-9-CM diagnostic codes. The database included an average of 40.8 million commercially insured enrollees under age 65 per year. Clinical, demographic and healthcare utilization criteria were used to identify patient subgroups early in their episode who were at risk to have high inpatient expenditures. Healthcare expenditures of patients within each subgroup were bifurcated: those expenditures that remained five days after the patient could be classified into the subgroup versus those that had occurred previously.

Results
The hospitalization episode rate per 100,000 enrollee-years for meningitis was 13.0 (95% CI: 12.9-13.2) and for encephalitis was 4.3 (95% CI: 4.2-4.4), with mean inpatient expenditures of $36,891 (SD = $92,636) and $60,181 (SD = $130,276), respectively. If advanced diagnostic testing had been administered on the day that a patient could be classified into a subgroup, then a test with a five-day turnaround time could impact the following mean inpatient expenditures that remained by subgroup for patients with meningitis or encephalitis, respectively: had a neurosurgical procedure ($83,337 and $56,020), had an ICU stay ($34,221 and $46,051), had HIV-1 infection or a previous organ transplant ($37,702 and $62,222), were age <1 year ($35,371 and $52,812), or had a hospital length of stay >2 days ($18,325 and $30,244).

Discussion
Inpatient expenditures for patients hospitalized with meningitis or encephalitis were substantial and varied widely. Patient subgroups who had high healthcare expenditures could be identified early in their stay, raising the potential for advanced diagnostic testing to lower these expenditures.

Exploratory analysis of the potential for advanced diagnostic testing to reduce healthcare expenditures of patients hospitalized with meningitis or encephalitis

Brent D. Fulton, Conceptualization, Data curation, Formal analysis, Methodology, Project administration, Resources, Supervision, Writing - original draft, Writing - review & editing,1,* David G. Proudman, Conceptualization, Formal analysis, Methodology, Validation, Writing - original draft, Writing - review & editing,1 Hannah A. Sample, Formal analysis, Resources, Writing - review & editing,2 Jeffrey M. Gelfand, Formal analysis, Writing - review & editing,3 Charles Y. Chiu, Conceptualization, Funding acquisition, Writing - review & editing,4,5,6 Joseph L. DeRisi, Conceptualization, Funding acquisition, Writing - review & editing,2,7 and Michael R. Wilson, Conceptualization, Formal analysis, Funding acquisition, Writing - original draft, Writing - review & editing3 Sandra C. Buttigieg, Editor

2020

26870552

The title compound, C21H21NO5, crystallizes with two mol­ecules in the asymmetric unit. In each mol­ecule, the central 1,4-di­hydro­pyridine ring adopts a shallow sofa conformations (with the C atom bearing the phenol ring as the flap), whereas the pendant cyclo­hexene rings both have twisted-boat conformations. Each mol­ecule features an intra­molecular O—H⋯O hydrogen bond, which closes an S(8) ring. In the crystal, the mol­ecules are linked by O—H⋯O, C—H⋯O and C—H⋯π inter­actions, forming a three-dimensional network.

crystal structure, acridines, acetic acid, hydrogen bonding, C—H⋯π inter­actions

Crystal structure of 2-[9-(2-hy­droxy­phen­yl)-1,8-dioxo-1,2,3,4,5,6,7,8,9,10-deca­hydro­acridin-10-yl]acetic acid

Mehmet Akkurt,a Jerry P. Jasinski,b Shaaban K. Mohamed,c,d Omyma A. Abd Allah,e Asmaa H. A. Tamam,e and Mustafa R. Albayatif,*

2015 Dec 1;